This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
27 October 2022 – The September quarter (Q1 FY 2023) was highlighted by the Raceteam’s development of an improved and novel formulation of the company’s lead drug,Zantrene which enables peripheral intravenous (IV) delivery (ASX Announcement: 28September 2022). The manufacture of the new formulation (codenamed RC220) has beencontracted to Societal (San Diego, CA, USA) with an…
-
Pitt Street Research Initiates Coverage of Race Oncology
Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent as well as a chemotherapy cardioprotective. The drug is the most potent small molecule inhibitor…
-
Race Develops Improved IV Formulation of Zantrene
To discuss or comment on this announcement please visit our Investor Hub.
-
Race Initiates FTO & ALKBH5 Drug Discovery Program
To discuss or comment on this announcement please visit our Investor Hub.
-
Race Oncology June 2022 Quarterly Investor Briefing
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.
-
Zantrene Protects Mouse Hearts from Chemotherapy Damage
30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021). This program aimed at exploring the use of Zantrene® (bisantrene dihydrochloride) as a cardioprotective agent which offered synergy with anti-cancer treatments.…